EGFR mutation analysis for prospective patient (pt) selection in AURA3 Phase III trial of osimertinib vs platinum-pemetrexed (plt-pem) in pts with EGFR T790M positive advanced non-small cell lung cancer (NSCLC)

Authors :: Thomas John
Simon Dearden
Hiroaki Akamatsu
W-C Su
J-S. Lee
Y-L. Wu
Suzanne Jenkins
X. Huang
Angelo Delmonte
G-C. Chang
Source :: Annals of Oncology. 28:x128
Publication Year :: 2017
Publisher :: Elsevier BV, 2017.

Subjects :: Oncology
030213 general clinical medicine
medicine.medical_specialty
business.industry
non-small cell lung cancer (NSCLC)
EGFR T790M
Hematology
medicine.disease
03 medical and health sciences
0302 clinical medicine
Pemetrexed
030220 oncology & carcinogenesis
Internal medicine
medicine
Mutation testing
Osimertinib
business
Selection (genetic algorithm)
medicine.drug

Full Text Access

Tools